IMMU Immunicum AB

Mendus to hold Business Update event on March 12

Mendus to hold Business Update event on March 12

Press Release

Stockholm, Sweden, February 23, 2024



Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company’s latest pipeline advancements.

Mendus has recently presented positive Phase 2 data with vididencel in acute myeloid leukemia (AML), an aggressive blood-borne tumor associated with high relapse rates, at the ASH 2023 conference. Vididencel addresses the need for safe and effective AML maintenance treatments, which prolong disease-free and overall survival following initial chemotherapy.

Based on the positive data in AML, Mendus will expand the clinical development of vididencel in combination with standard of care in a randomized controlled trial together with the Australasian Leukaemia and Lymphoma Group (ALLG). To facilitate late-stage development and prepare for commercial launch, Mendus is scaling up the vididencel manufacturing capacity together with NorthX Biologics, a leading Nordic contract development and manufacturing organization for cell and gene therapies.

At the business update event, Mendus will present together with its strategic partners ALLG and NorthX Biologics the next steps in the development of vididencel as a promising new maintenance treatment option for AML patients.

The live presentation will be in English and followed by a question-and-answer session. Guests are welcome to stay and mingle with management afterwards.



Venue: Inderes Event Studio (Västra Trädgårdsgatan 19, Stockholm)

Date and time: March 12 at 15:00–17:00 CET, registration is open from 14:30



Please register to attend via email to

Those unable to attend in person can listen to the presentation webcast:

Questions can be sent ahead of the presentation to



For more information, please contact:

Erik Manting, CEO

E-mail:

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Attachment



EN
23/02/2024

Underlying

IMMUImmunicum AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immunicum AB

Free Trial
IMMU IMMUNICUM AB

Mendus AB: 2 directors

A director at Mendus AB bought 65,000 shares at 5.298SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

06/12/25 June 12, 2025 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Collaboration unveils path forward for ilixadencel

Mendus has announced a collaboration with Institut Bergonié, an established comprehensive cancer centre in France, to test ilixadencel in soft tissue sarcomas (STS) as part of an ongoing Phase I/II basket trial (REGOMUNE). The trial is a multi-centre, prospective open-label study assessing the combination of regorafenib (a tyrosine kinase inhibitor) and avelumab (an immune checkpoint inhibitor) in various solid tumours. Ilixadencel will be evaluated along with a combination in one of the treatme...

07/24/24 July 24, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Recent clinical data highlight vididencel’s potential

Mendus recently presented positive data from two ongoing clinical studies, ADVANCE II and ALISON, at the EHA and ESMO conferences, respectively. While the Phase I ALISON trial, evaluating lead asset vididencel in ovarian cancer, met its primary endpoint of generating sufficient vaccine-induced responses (VIR), further analysis of ADVANCE II data (studying vididencel as a maintenance therapy in AML) confirmed the drug’s potential in generating a broader immune response through both T-cell and B-c...

06/21/24 June 21, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - All hands on deck as inflection points approach

With Mendus’s Q124 results, management recapped its clinical priorities, which are all progressing as expected. The focus remains on the AMLM22-CADENCE trial for lead cancer vaccine vididencel, in combination with oral azacitidine as a maintenance treatment for acute myeloid leukaemia (AML). R&D expenses came in slightly ahead of expectations with the ramp up in clinical activity, including preparation for the subsequent pivotal Phase III trial, with large-scale manufacturing of vididencel (plan...

05/20/24 May 20, 2024 1 EN
Sean Conroy
  • Sean Conroy
IMMU IMMUNICUM AB

Mendus - Gross proceeds of c SEK69m to advance pipeline

Mendus has reported gross proceeds of c SEK69.1m from the exercise of series TO3 warrants that were issued in connection with the July 2023 raise of SEK317m. Management anticipates that these proceeds will extend the cash runway to Q325 and will be applied to progress its clinical pipeline, mainly in preparation for a registrational trial for lead cancer vaccine vididencel, targeting acute myeloid leukaemia (AML) in the maintenance setting. Management expects the registrational study to commence...

04/04/24 April 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch